comprehensive -WSS

comprehensive

author：explore 2025-10-01 00:59:47 - browse：9873

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Publishing genetic code of viruses could cause disaster

WSS

FDA panel gives mixed vote on blood pressure devices

How state and local governments are sidelining science

A letter from the executive editor: STAT UnitedHealth investigation

Publishing genetic code of viruses could cause disaster

What health policies could hitch a ride on a spending bill?

Study suggests Covid rebound is far more common with Paxlovid than without

Wikipedia

comprehensive

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Departing Stanford president retracts two papers

Trump demands the U.S. pay no more for drugs than other countries … again

FDA reorg will put new emphasis on investigations, sources say

Continuity nursing helped my family in our darkest PICU moments

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Novavax promises a turnaround & Lilly roils the obesity market

Departing Stanford president retracts two papers

Affirmative action in medical school literally saved lives

Why more medical students aren't specializing in primary care

focus

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

White House drug czar issues call for 'recovery

How a symptom of dementia informs our understanding of creativity

AstraZeneca challenges Medicare drug negotiation program

A letter from the executive editor: STAT UnitedHealth investigation

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

entertainment

explore

hotspot

entertainment